Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Viracta Therapeutics Completes Second-Stage Enrollment Into Peripheral T-Cell Lymphoma Cohort Of NAVAL-1 Trial

Author: Benzinga Newsdesk | February 29, 2024 09:42am

Accelerated pace of enrollment supports speed to market strategy

Topline results from Stage 1 expected to be presented in the second quarter of 2024 followed by Stage 2 data in the third quarter of 2024

Posted In: VIRX